Division of Retrovirology, National Institute for Biological Standards and Control, Health Protection Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.
PLoS One. 2011;6(8):e23092. doi: 10.1371/journal.pone.0023092. Epub 2011 Aug 10.
Live attenuated simian immunodeficiency virus (SIV) vaccines represent the most effective means of vaccinating macaques against pathogenic SIV challenge. However, thus far, protection has been demonstrated to be more effective against homologous than heterologous strains. Immune correlates of vaccine-induced protection have also been difficult to identify, particularly those measurable in the peripheral circulation.
METHODOLOGY/PRINCIPAL FINDINGS: Here we describe potent protection in 6 out of 8 Mauritian-derived cynomolgus macaques (MCM) against heterologous virus challenge with the pathogenic, uncloned SIVsmE660 viral stock following vaccination with live attenuated SIVmac251/C8. MCM provided a characterised host genetic background with limited Major Histocompatibility Complex (MHC) and TRIM5α allelic diversity. Early protection, observed as soon as 3 weeks post-vaccination, was comparable to that of 20 weeks vaccination. Recrudescence of vaccine virus was most pronounced in breakthrough cases where simultaneous identification of vaccine and challenge viruses by virus-specific PCR was indicative of active co-infection. Persistence of the vaccine virus in a range of lymphoid tissues was typified by a consistent level of SIV RNA positive cells in protected vaccinates. However, no association between MHC class I/II haplotype or TRIM5α polymorphism and study outcome was identified.
CONCLUSION/SIGNIFICANCE: This SIV vaccine study, conducted in MHC-characterised MCM, demonstrated potent protection against the pathogenic, heterologous SIVsmE660 challenge stock after only 3 weeks vaccination. This level of protection against this viral stock by intravenous challenge has not been hitherto observed. The mechanism(s) of protection by vaccination with live attenuated SIV must account for the heterologous and early protection data described in this study, including those which relate to the innate immune system.
活减毒猴免疫缺陷病毒(SIV)疫苗是给猕猴接种预防致病性 SIV 感染最有效的方法。然而,迄今为止,疫苗的保护作用被证明对同源性病毒株比异源性病毒株更有效。疫苗诱导的保护性免疫相关因素也难以确定,尤其是在周围循环中可测量的那些因素。
方法/主要发现:在这里,我们描述了 8 只毛里求斯猕猴(MCM)中有 6 只在接种活减毒 SIVmac251/C8 后,针对具有致病性的未克隆 SIVsmE660 病毒株的异源性病毒挑战,表现出强烈的保护作用。MCM 提供了一个具有有限主要组织相容性复合体(MHC)和 TRIM5α 等位基因多样性的特征宿主遗传背景。早期保护作用早在接种后 3 周就观察到,与 20 周接种的保护作用相当。突破病例中,疫苗病毒的重新出现最为明显,病毒特异性 PCR 同时鉴定疫苗和挑战病毒表明存在活跃的合并感染。疫苗病毒在一系列淋巴组织中的持续存在以受保护的接种者中 SIV RNA 阳性细胞的一致水平为特征。然而,未发现 MHC Ⅰ/Ⅱ类单倍型或 TRIM5α 多态性与研究结果之间存在关联。
结论/意义:这项在 MHC 特征化的 MCM 中进行的 SIV 疫苗研究表明,在接种仅 3 周后,对具有致病性的异源性 SIVsmE660 挑战株具有强大的保护作用。静脉内挑战对这种病毒株的这种保护水平迄今尚未观察到。活减毒 SIV 接种的保护机制必须解释本研究中描述的异源性和早期保护数据,包括与先天免疫系统相关的那些数据。